Rein Therapeutics (RNTX) Other Non-Current Assets (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Other Non-Current Assets of $2000.0 for Q4 2025, little changed year-over-year from $2000.0 in Q4 2024, and little changed quarter-over-quarter from $2000.0 in Q3 2025.
Rein Therapeutics (RNTX) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Other Non-Current Assets for 10 consecutive years, with $2000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $2000.0; the TTM figure through Dec 2025 stood at $2000.0 (changed 0.0% YoY), while the FY2025 annual figure was $2000.0, changed 0.0% from the prior year.
- Other Non-Current Assets was little changed at $2000.0 in Q4 2025 per RNTX's latest filing, from $2000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $2.2 million in Q4 2023 and bottomed at $2000.0 in Q2 2024.
- Historically, Other Non-Current Assets has averaged $206350.0 across 5 years, with a median of $24000.0 in 2021.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets surged 9037.5% — and 2024, when it tumbled 99.91%.
- Rein Therapeutics' Other Non-Current Assets stood at $24000.0 in 2021, then changed by 0.0% to $24000.0 in 2022, then soared by 9037.5% to $2.2 million in 2023, then sank by 99.91% to $2000.0 in 2024, then changed by 0.0% to $2000.0 in 2025.
- Business Quant data shows RNTX's Other Non-Current Assets at $2000.0 in Q4 2025, $2000.0 in Q3 2025, and $2000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | 1.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 766,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 2,000.00 |
| Mar 31, 2024 | 892,000.00 |
| Dec 31, 2023 | 2.19 Mn |
| Sep 30, 2023 | 25,000.00 |
| Jun 30, 2023 | 25,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Dec 31, 2022 | 24,000.00 |
| Sep 30, 2022 | 24,000.00 |
| Jun 30, 2022 | 24,000.00 |
| Mar 31, 2022 | 24,000.00 |
| Dec 31, 2021 | 24,000.00 |
| Sep 30, 2021 | 24,000.00 |